First licensed treatment for ultra-rare immune disorder recommended
Leniolisib is the first ever treatment for activated phosphoinositide 3-kinase delta syndrome (APDS) licensed for use in the NHS in England.
Our recommendations help practitioners and commissioners get the best care to people, fast, while ensuring value for the taxpayer.
Leniolisib is the first ever treatment for activated phosphoinositide 3-kinase delta syndrome (APDS) licensed for use in the NHS in England.
At its meeting on 19 March our Board approved changes to the criteria we use to decide which treatments should be evaluated, to ensure more consistent, predictable and transparent decisions.
We've published a draft quality standard calling for yearly BMI and waist-to-height measurements to help prevent weight-related complications.
Today we've recommended the first long-term daily pill to treat endometriosis that could transform how this painful condition is managed.
Best practice resources for practitioners and commissioners.
Useful sources of information and advice for healthcare professionals, patients, parents and carers.
Summaries of evidence and advice on common health topics (CKS)
On NICE’s 25th anniversary, our partners and collaborators in the health care system discuss what the future holds for NICE.